A Phase II Study Comparing Two Dose Levels of Bupropion versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

Share
Print

Full Title

Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer (NRG-CC004) (CIRB)

Purpose

Treatment for breast and gynecologic cancers can sometimes reduce sexual desire. In this study, researchers are assessing two dose levels of bupropion in women who have been treated for breast or gynecologic cancer and are experiencing decreased sexual health. Bupropion is already used to treat depression and to help people who want to stop smoking.

Participants will be randomly assigned either to one of two doses of bupropion or to a placebo, all of which are taken orally (by mouth). They will complete several questionnaires about their sexual health and well-being before, during, and after taking the study medication.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have had treatment for breast or a gynecologic cancer and be experiencing reduced sexual health.
  • Initial treatment must have ended 6 or more months before entering the study, though continued treatment with trastuzumab or hormonal therapy is permitted.
  • Participants must be in menopause (as a result of age or treatment).
  • This study is for women age 18 and older.

For more information about this study, please contact Dr. Jeanne Carter at 646-888-5077.

Protocol

19-409

Phase

II

Investigator